-
Signature
-
/s/ Stephen Feider, Attorney-in-Fact
-
Issuer symbol
-
BBNX
-
Transactions as of
-
27 Feb 2026
-
Net transactions value
-
$0
-
Form type
-
4/A - Amendment
-
Filing time
-
13 Mar 2026, 16:15:17 UTC
-
Date Of Original Report
-
03 Mar 2026
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Hopman Mark |
Chief Commercial Officer |
C/O BETA BIONICS, INC., 11 HUGHES, IRVINE |
/s/ Stephen Feider, Attorney-in-Fact |
13 Mar 2026 |
0002048497 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
BBNX |
Employee Stock Option (right to buy) |
Award |
|
+91,520 |
|
$0.000000* |
91,520 |
27 Feb 2026 |
Common Stock |
91,520 |
$12.63 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.